Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori

• Published in: European journal of gastroenterology & hepatology Vol. 7 Suppl 1; p. S45
• Main Authors: Fukuda, Y, Yamamoto, I, Okui, M, Tonokatsu, Y, Tamura, K, Shimoyama, T
• Format: Journal Article
• Language: English
• Published: England 01.08.1995
• Subjects: Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - therapeutic use; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - therapeutic use; Biopsy; Clarithromycin - administration & dosage; Clarithromycin - therapeutic use; Colony Count, Microbial; Drug Therapy, Combination; Fatty Alcohols - administration & dosage; Fatty Alcohols - therapeutic use; Gastric Mucosa - drug effects; Gastric Mucosa - microbiology; Gastroscopy; Helicobacter Infections - complications; Helicobacter Infections - drug therapy; Helicobacter Infections - microbiology; Helicobacter pylori - drug effects; Helicobacter pylori - isolation & purification; Humans; Stomach Ulcer - drug therapy; Stomach Ulcer - microbiology
• ISSN: 0954-691X

To investigate the effect of plaunotol in combination with proton-pump inhibitors on Helicobacter pylori eradication in patients with gastric ulcer. We studied 65 H. pylori-positive gastric ulcer patients. They were randomly assigned to five treatment groups: omeprazole (group I, n = 8), lansoprazole (group II, n = 13), lansoprazole+plaunotol (group III, n = 12), lansoprazole+clarithromycin (group IV, n = 16) and lansoprazole+plaunotol+clarithromycin (group V, n = 16). Ulcer status was diagnosed by endoscopy and H. pylori status by culture, histology, a urease test and a urea breath test at baseline, and after 8 and 12 weeks. The clearance and eradication rates were compared in each group. The healing rates in groups I-V were 100, 92, 100, 100 and 100%, respectively; clearance rates were 0, 23, 42, 50 and 75%, respectively; and eradication rates were 0, 0, 8, 38 and 69%, respectively. Combination therapy with plaunotol is efficacious for the eradication of H. pylori in gastric ulcer patients.